Viekira On Blockbuster Pace As AbbVie Adds Second HCV Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The HCV combo product does better than expected internationally but disappoints in the U.S. Strong quarter was marked by overall sales growth for Humira, but slowing growth ex-U.S., where biosimilar adalimumab is available.